Vaccine Antigens against Acinetobacter baumannii
Novel Antigens for Preventing the Nosocomial Bacterial Infection
Targeted indication
Prevention of A. baumannii infection
Status
Proof of concept/preclinical studies
Key features
- Conserved virulence factors
- Eliciting long-term immunity
- No obvious side effects
Market
Antimicrobial resistance has evolved to become a worldwide health threat. According to the RAND EUROPE reports, drug-resistant superbugs will kill more people than cancer and cost up to $100 trillion by 2050. Bacteria that cause nosocomial infection including Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae are classified by WHO as the priority 1 pathogens which new drugs are most urgently needed.
Vaccination is the most effective strategy to prevent infectious diseases.
The COVID-19 pandemics reminds us that life is unpredictable. New diseases and accidents may happen suddenly. Vaccination with A. baumannii vaccine may protect individuals from the nosocomial infections or at least to reduce the disease severity when hospitalized.
MODE OF ACTION
EXPERIMENTAL RESULTS
The vaccine potential of each antigen has been demonstrated by immunizing mice with the individual antigen three times and then challenging with the reference strain ATCC 17978 or a hypervirulent strain.
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
NA
BUSINESS OPPORTUNITY
License and/or Collaboration and Sponsored Research
CONTACT
service@biip-dcc.org